926922-22-7Relevant articles and documents
9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: Design, synthesis, and biological evaluation
Huang, Wei-Sheng,Zhu, Xiaotian,Wang, Yihan,Azam, Mohammad,Wen, David,Sundaramoorthi, Raji,Thomas, R. Mathew,Liu, Shuangying,Banda, Geetha,Lentini, Scott P.,Das, Sasmita,Xu, Qihong,Keats, Jeff,Wang, Frank,Wardwell, Scott,Ning, Yaoyu,Snodgrass, Joseph T.,Broudy, Marc I.,Russian, Karin,Daley, George Q.,Iuliucci, John,Dalgarno, David C.,Clackson, Tim,Sawyer, Tomi K.,Shakespeare, William C.
experimental part, p. 4743 - 4756 (2010/03/03)
A novel series of potent dual Src/Abl kinase inhibitors based on a 9-(arenethenyl)purine core has been identified. Unlike traditional dual Src/Abl inhibitors targeting the active enzyme conformation, these inhibitors bind to the inactive, DFG-out conformation of both kinases. Extensive SAR studies led to the discovery of potent and orally bioavailable inhibitors, some of which demonstrated in vivo efficacy. Once-daily oral administration of inhibitor 9i (AP24226) significantly prolonged the survival of mice injected intravenously with wild type Bcr-Abl expressing Ba/F3 cells at a dose of 10 mg/kg. In a separate model, oral administration of 9i to mice bearing subcutaneous xenografts of Src Y527F expressing NIH 3T3 cells elicited dose-dependent tumor shrinkage with complete tumor regression observed at the highest dose. Notably, several inhibitors (e.g., 14a, AP24163) exhibited modest cellular potency (IC50 = 300-400 nM) against the Bcr-Abl mutant T315I, a variant resistant to all currently marketed therapies for chronic myeloid leukemia. 2009 American Chemical Society.
UNSATURATED HETEROCYCLIC DERIVATIVES
-
Page/Page column 39, (2008/06/13)
This invention relates to compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.
Facile synthesis of 9-(arenethenyl)purines via Heck reaction of 9-vinylpurines and aryl halides
Huang, Wei-Sheng,Wang, Yihan,Sundaramoorthi, Raji,Thomas, R. Mathew,Wen, David,Liu, Shuangying,Lentini, Scott P.,Das, Sasmita,Banda, Geetha,Sawyer, Tomi K.,Shakespeare, William C.
, p. 7388 - 7391 (2008/03/13)
The first example of a Heck reaction with 9-vinylpurines and aryl halides is described. It gives exclusively E-9-(arenethenyl)purines in high yields. Subsequent hydrogenation furnishes 9-(arenethyl)purines quantitatively.
